chantix

What chantix does

CHANTIX is a Pfizer-branded prescription pharmaceutical product containing varenicline tartrate, a nicotinic receptor partial agonist selective for the alpha4beta2 nicotinic acetylcholine receptor subtype. The drug binds with high affinity to these receptors, producing moderate agonist activity to reduce nicotine withdrawal while simultaneously blocking nicotine from binding and triggering the central mesolimbic dopamine reward pathway. It is indicated as an aid to smoking-cessation treatment in adult smokers and has been studied across multiple subpopulations including patients with stable cardiovascular disease, mild-to-moderate COPD, major depressive disorder, and schizophrenia/schizoaffective disorder.

The product is commercially available in two oral tablet strengths (0.5 mg and 1 mg) and is dispensed exclusively through licensed retail and hospital pharmacies following a valid prescription. Three dosing regimens are supported by the label: a fixed quit-date approach (begin dosing one week before the quit date), an alternative quit-date approach (quit between days 8-35), and a gradual-approach regimen (reduce smoking 50% in the first four weeks, then 50% again, with target abstinence by week 12). The standard course is 12 weeks, with an additional 12-week course recommended for successful quitters to increase long-term abstinence. In clinical trials of N=3,659 chronic smokers, CHANTIX 1 mg twice daily achieved CO-confirmed continuous abstinence rates of 44% during weeks 9-12 versus 17-18% for placebo and 30% for bupropion SR, with long-term (weeks 9-52) abstinence of 21-23% versus 4-10% for placebo.

CHANTIX is owned and manufactured by Pfizer Laboratories Div Pfizer Inc, a division of Pfizer Inc (NYSE: PFE). The product received initial U.S. FDA approval in 2006, and the prescribing information was most recently revised in June 2025, indicating ongoing commercial availability. Revenue, pricing, and headcount dedicated to CHANTIX are not disclosed in the available materials. Pfizer markets the product through healthcare professional detailing, direct-to-consumer advertising, a dedicated website (www.CHANTIX.com), and a toll-free information line. The label carries significant safety warnings including neuropsychiatric events, seizures, alcohol interaction, cardiovascular events, somnambulism, angioedema, and serious skin reactions, which materially shape prescribing behavior and patient eligibility.

Name

chantix

Legal name

Pfizer Laboratories Div Pfizer Inc

Website

https://chantix.com

Company type

Public

Founded year

2006

Operating status

Operating

Short description

CHANTIX is Pfizer's branded prescription varenicline tartrate drug, a nicotinic receptor partial agonist used as an aid to smoking cessation in adult smokers. Available as 0.5 mg and 1 mg oral tablets, it is dispensed through retail and hospital pharmacies.

Ownership category

akta.pro rank

Product category

Smoking Cessation Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Nicotine Replacement Therapy (NRT) Consumer Products Manufacturing & Brands (CRADAJAJ)

Keywords

• Smoking cessation medication
• Prescription pharmaceuticals
• Varenicline tablets
• Nicotinic receptor agonists
• Nicotine addiction treatment

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Marketing or Sales, Technology or R&D, Personnel

Distribution channels1 record

Marketing channels3 records

Core offering

CHANTIX is a prescription-only oral pharmaceutical (varenicline tartrate) sold in 0.5 mg and 1 mg tablet strengths as an aid to adult smoking-cessation treatment. The drug acts as a partial agonist at alpha4beta2 nicotinic acetylcholine receptors to reduce withdrawal symptoms and block nicotine's rewarding effects, and is available through standard retail, hospital, and mail-order pharmacy channels following a valid prescription.

Product overview

CHANTIX is a prescription pharmaceutical product containing varenicline tartrate as its active ingredient. It is available in two tablet strengths: 0.5 mg (white to off-white) and 1 mg (light blue). CHANTIX acts as a nicotinic receptor partial agonist selective for α4β2 nicotinic acetylcholine receptor subtypes, blocking nicotine's ability to activate these receptors while reducing cravings and withdrawal symptoms associated with smoking cessation.

Differentiator

Problem solved

Functional benefit

Products and services

• CHANTIX 0.5 mg tablets White to off-white, film-coated, capsular biconvex oral tablet containing varenicline tartrate equivalent to 0.5 mg of varenicline free base; a nicotinic receptor partial agonist indicated as an aid to smoking-cessation treatment in adults, used during the starting week of therapy and in renally impaired patients.
• CHANTIX 1 mg tablets Light blue, film-coated, capsular biconvex oral tablet containing varenicline tartrate equivalent to 1 mg of varenicline free base; a nicotinic receptor partial agonist indicated as an aid to smoking-cessation treatment in adults, dosed at 1 mg twice daily during the continuing weeks of therapy.

Quantifiable outcome

• In six clinical trials (N=3659 chronic smokers), CHANTIX 1 mg twice daily achieved CO-confirmed continuous abstinence rates of 44% during weeks 9-12 compared to 17-18% for placebo and 30% for bupropion SR
• +5 more outcomes

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• British American Tobacco: Global tobacco company whose Vuse brand is a leading closed-system e-cigarette. Markets reduced-risk products that compete with both CHANTIX and traditional NRT for adult smokers seeking non-combustible alternatives.
• Philip Morris International: Global tobacco incumbent marketing IQOS heated-tobacco and other reduced-risk products across international markets. Competes with CHANTIX for share of adult smokers pursuing cigarette alternatives, particularly outside the U.S.
• Altria Group: U.S. tobacco holding company with on! nicotine pouches, NJOY exposure, and historical NRT investments. Operates across both combustible and smoke-free adult tobacco categories that overlap with CHANTIX's cessation-focused use case.
• GSK: Originally developed and markets bupropion SR (Zyban) for smoking cessation, the principal prescription comparator CHANTIX was benchmarked against in pivotal trials. GSK's broader pharma portfolio makes it a broad incumbent operating across the same cessation therapeutic space.

Direct peers

• Apotex: Canadian-headquartered generic pharmaceutical manufacturer with approved generic varenicline tartrate in U.S. and Canadian markets. Adds another directly substitutable competitor pressing on CHANTIX's branded script economics.
• Haleon: Owns and markets the Nicorette and Nicoderm/Nicotrol NRT brands (gum, lozenge, patch). Haleon is the most direct consumer-facing competitor to CHANTIX in the smoking-cessation category, targeting the same adult smokers via retail pharmacy channels.
• Teva Pharmaceutical Industries: Generic pharmaceutical manufacturer with U.S. FDA-approved generic varenicline. Competes head-to-head with Pfizer's branded CHANTIX on price and formulary positioning in retail and mail-order pharmacy channels.
• Aurobindo Pharma: Generic pharmaceutical manufacturer with U.S. FDA-approved generic varenicline tartrate tablets. Direct substitutable competitor now capturing the majority of generic volume that previously belonged to branded CHANTIX.

Emerging players

• NJOY: U.S. e-cigarette company with FDA-authorized menthol and tobacco-flavored vaping products. Targets the same adult smokers as a non-prescription, off-ramp alternative to pharmacotherapy cessation.
• Achieve Life Sciences: Developing cytisinicline (cytisine-based therapy) as a novel prescription smoking cessation aid in the U.S. market. Targeting the same physician-prescribed cessation segment as CHANTIX with a plant-derived alternative mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about chantix